Skip to main content
Prime Medicine, Inc. logo

Prime Medicine, Inc. — Investor Relations & Filings

Ticker · PRME ISIN · US74168J1016 US Manufacturing
Filings indexed 259 across all filing types
Latest filing 2025-05-19 Board/Management Inform…
Country US United States of America
Listing US PRME

About Prime Medicine, Inc.

https://primemedicine.com/

Prime Medicine, Inc. is a biotechnology company focused on developing a new class of one-time, curative genetic therapies. The company's approach is centered on its proprietary Prime Editing platform, a next-generation gene editing technology. Prime Editing is designed to function like a precise 'search and replace' mechanism for the genome, capable of correcting a wide range of disease-causing genetic mutations. It can perform insertions, deletions, and all types of point mutations without inducing double-strand DNA breaks, a key differentiator from some earlier gene editing techniques. The company's mission is to address the root genetic cause of debilitating diseases, aiming to provide patients with potentially lifelong therapeutic benefits.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the departure of the CEO and other officers, appointment of a new CEO and board member, details of employment agreements, and other management changes. It also references press releases and a corporate presentation but does not itself contain financial statements or detailed financial results. The primary focus is on changes in the company's board and senior management. Therefore, this filing fits the category of Board/Management Information (MANG). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to the clear focus on management changes and the use of Form 8-K for such disclosures.
2025-05-19 English
FORM 4
Director's Dealing
2025-05-12 English
FORM 4
Director's Dealing
2025-05-12 English
FORM 4
Director's Dealing
2025-05-12 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2025, by Prime Medicine, Inc. It specifically mentions "Item 2.02 Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results and business highlights for the quarter ended March 31, 2025. The document includes a press release as Exhibit 99.1. The text clarifies that the information is furnished and not filed, and it is a current report rather than a full quarterly or annual report. The document length is 3703 characters, which is relatively short and consistent with a current report or earnings release announcement. The key indicator is the announcement of quarterly financial results via a press release, which aligns with the definition of an Earnings Release (ER). Therefore, the document is best classified as an Earnings Release (ER).
2025-05-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.